500 UNICORN PARK, WOBURN, MA
Earnings Release
Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Igniting a Systemic Immune Response to Cancer with Oncolytic Immunotherapy
Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Submission Upload
Correspondence